recording

POSTERS ESMO 2024

esmo

Cáncer urotelial

Alvaro Pinto Marín

acceso

Prediction of response and identification of mechanisms of resistance to neoadjuvant chemotherapy according to molecular subtypes in muscle-invasive bladder carcinoma

  • Alvaro Pinto Marín

    Hospital Universitario La Paz. Madrid
Begoña Pérez Valderrama

acceso

Post hoc analysis of outcomes according to prior chemotherapy (CT) response and platinum agent in the international SAUL study of atezolizumab (atezo) for urinary tract carcinoma (UTC)

  • Begoña Pérez Valderrama

    Hospital Universitario Virgen del Rocío. Sevilla
Felix Guerrero-Ramos

acceso

Urine-based molecular testing identifies FGFR alteration–positive patients for treatment with TAR-210

  • Felix Guerrero-Ramos

    Hospital Universitario 12 de Octubre. Madrid
Pol Servian

acceso

RUTIVAC-1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase I Trial to Evaluate the Immunomodulatory Effect of RUTI® in Individuals with High-Risk Non-Muscle-Invasive Bladder Cancer Treated with Intravesical BCG.

  • Pol Servian

    Hospital Universitario Hermanos Trias y Pujol. Badalona

Una iniciativa científica de:

eco clover

Con el patrocinio de:

REGENERON